Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts.